Panacea Biotec Limited

BSE: 531349 NSE: PANACEABIO
Panacea Biotec Limited - life sciences in Lalru, Punjab, India. FY 2026 financials & compliance.
CIN L33117PB1984PLC022350 Incorporated 02 February 1984 ROC Chandigarh HQ Lalru, Punjab, India
Active Listed - NSE: PANACEABIO · BSE: 531349 Public Limited Company life sciences
Data last updated
Market Cap
₹2,110 Cr
PANACEABIO · NSE
Share Price
₹345.25
+0.22% today
Revenue
₹640 Cr
FY 2025-26 · +14.4% YoY
EBITDA
−₹4.66 Cr
Margin -0.7%
Net Profit
−₹24.44 Cr
FY 2025-26 · +42.7% YoY
Authorised capital
₹122.34 Cr
Registered with MCA
Paid-up capital
₹22.26 Cr
Issued & subscribed
Open charges
₹739.69 Cr
Satisfied ₹3,545.32 Cr

About Panacea Biotec Limited

Data last updated:

Panacea Biotec Limited is a public limited company based in Lalru, Punjab, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 02 February 1984 and has been in existence for over 42 years.

The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN L33117PB1984PLC022350. Its GSTIN is 03AAACP5335J1ZM (Punjab). The company holds 25 GST registrations, of which 23 are active. Its shares are listed on BSE: 531349 and NSE: PANACEABIO.

The company has an authorised share capital of ₹122.34 Cr and a paid-up capital of ₹22.26 Cr. It was formerly known as Panacea Drugs Ltd and Panacea Drugs Pvt Ltd. It is led by directors including Sandeep Jain (Managing Director) and Rajesh Jain (Managing Director).

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Ambala – Chandigarh Highway, Lalru, Punjab, India – 140501.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹639.77 Cr, a growth of 14.4% compared to the previous year. For the same year it recorded a net loss of ₹24.44 Cr (net margin -3.8%) and EBITDA of -₹4.66 Cr (EBITDA margin -0.7%). The net worth stands at ₹843.5 Cr (up 0.2% YoY). Total assets are valued at ₹890.34 Cr (down 1% YoY).

The company has about 1,173 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries and 1 joint venture.

As per MCA filings, the company has open charges of ₹739.69 Cr and satisfied charges of ₹3,545.32 Cr on record. Court records list 18 cases involving the company, including 14 filed by the company and 4 filed against it; 2 cases are pending.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website panaceabiotec.com.

Company Details of Panacea Biotec Limited
CIN L33117PB1984PLC022350
Registration Number 022350
Incorporation Date 02 February 1984
ROC Chandigarh
Listing Status Listed (BSE: 531349, NSE: PANACEABIO)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sandeep Jain Managing Director Rajesh Jain Managing Director Ankesh Jain Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    panaceabiotec.com
  • Social Media
    Locked
  • Registered Address
    Ambala – Chandigarh Highway, Lalru, Punjab, India – 140501
  • Industry
    Life Sciences, Biotechnology
Comprehensive company report
Panacea Biotec Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Panacea Biotec Limited report

Financials, compliance, directors, charges, ownership and filings for Panacea Biotec Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Financials of Panacea Biotec Limited FY 2025-26 filings available

Panacea Biotec Limited reported revenue of ₹639.77 Cr (up 14.4% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹640 Cr
+14.4% YoY
EBITDA
−₹4.66 Cr
+82.0% YoY
Profit After Tax
−₹24.44 Cr
+42.7% YoY
Net Worth
₹844 Cr
+0.2% YoY
Total Assets
₹890 Cr
-1.0% YoY
Total Debt
₹15.00 Cr
0.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue640559559460661625544
Revenue growth+14.4%-0.0%+21.6%-30.4%+5.8%+14.8%-
EBITDA(4.66)(25.92)(20.07)(97.96)(13.19)75.189.53
EBITDA margin-0.7%-4.6%-3.6%-21.3%-2.0%+12.0%+1.8%
Profit before tax(7.37)(7.96)1.4712.801,449(146)(178)
Net profit(24.44)(42.65)(33.97)(94.64)(197)(148)(160)
Net profit margin-3.8%-7.6%-6.1%-20.6%-29.8%-23.6%-29.4%
EPS (₹)(0.88)(1.37)(0.19)(5.43)176.05(24.11)(31.72)
Balance sheet
Total assets8908999099219838131,064
Net worth844842848849877(229)199
Total debt15.0015.0015.0015.2434.16820742
Cash & bank64.3710713922658313689.75
Net working capital154206136219169146357
Cash flow
Cash from operations16.69(27.37)(0.10)(422)(108)107(30.47)
Cash from investing(40.46)64.9810.234301,283(47.79)(34.52)
Cash from financing(1.06)(2.66)(2.81)(18.37)(1,176)(47.11)90.74
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue200167165141167133163147
Revenue growth (YoY)+19.7%+25.8%+1.0%-4.2%+44.1%---
Other income6.985.265.059.1016.9936.306.397.42
EBITDA5.672.5711.74(17.79)(1.18)(26.88)7.967.00
EBITDA margin+2.8%+1.5%+7.1%-12.6%-0.7%-20.3%+4.9%+4.8%
Depreciation7.907.888.458.348.398.428.988.68
Interest1.181.201.852.140.861.040.990.98
Profit before tax3.57(1.25)6.49(19.17)6.56(0.04)4.384.76
Tax1.37(0.25)2.60(5.16)2.601.95(0.06)0.05
Net profit2.20(1.00)3.89(14.01)3.96(1.99)4.444.71
EPS (₹)0.380.080.65(2.20)0.66(0.31)0.740.77
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue413310360257236344158
Revenue growth+33.4%-13.8%+39.9%+9.2%-31.5%+117.3%-
EBITDA(17.84)(6.92)14.15(62.62)(72.69)0.46(135)
EBITDA margin-4.3%-2.2%+3.9%-24.4%-30.9%+0.1%-85.2%
Profit before tax(43.90)(26.05)4.19(62.74)(93.59)(12.88)(136)
Net profit(29.93)(15.28)3.48(92.83)(93.60)(17.70)(122)
Net profit margin-7.2%-4.9%+1.0%-36.1%-39.8%-5.2%-77.0%
EPS (₹)(4.88)(2.49)0.58(14.29)(15.28)(2.36)(24.99)
Balance sheet
Total assets584572480448515594978
Net worth294321335331415508893
Total debt25622111997.4784.1665.0867.24
Cash & bank8.1262.1711.9643.2542.6988.9660.61
Net working capital18.4641.57(65.64)(51.66)2.1396.03454
Cash flow
Cash from operations(40.17)3.9433.07(10.74)(52.69)38.27(82.86)
Cash from investing(18.46)(60.60)(46.80)2.4139.54(37.32)(16.58)
Cash from financing22.5490.0712.829.019.83(7.20)109
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13511199.3190.8111267.9010876.64
Revenue growth (YoY)+20.0%+63.7%-8.4%+18.5%+97.4%---
Other income6.065.603.843.614.956.093.323.41
Total expenses12711110110511586.4793.0469.90
EBITDA7.300.30(1.38)(13.70)(3.02)(18.57)15.396.74
EBITDA margin+5.4%+0.3%-1.4%-15.1%-2.7%-27.3%+14.2%+8.8%
Depreciation4.474.184.894.914.774.915.215.09
Interest6.896.337.045.936.004.643.853.76
Profit before tax2.00(4.61)(9.47)(20.93)(8.84)(22.03)9.651.30
Tax0.61(4.43)(2.11)(5.29)(2.14)(9.64)0.000.01

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 11 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue200167165141167133163147
Revenue growth (YoY)+19.7%+25.8%+1.0%-4.2%+44.1%---
Other income6.985.265.059.1016.9936.306.397.42
EBITDA5.672.5711.74(17.79)(1.18)(26.88)7.967.00
EBITDA margin+2.8%+1.5%+7.1%-12.6%-0.7%-20.3%+4.9%+4.8%
Depreciation7.907.888.458.348.398.428.988.68
Interest1.181.201.852.140.861.040.990.98
Profit before tax3.57(1.25)6.49(19.17)6.56(0.04)4.384.76
Tax1.37(0.25)2.60(5.16)2.601.95(0.06)0.05
Net profit2.20(1.00)3.89(14.01)3.96(1.99)4.444.71
EPS (₹)0.380.080.65(2.20)0.66(0.31)0.740.77
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue640559559460661625544
Revenue growth+14.4%-0.0%+21.6%-30.4%+5.8%+14.8%-
Other income36.4056.6561.831541,68710.0530.02
Total expenses644585579558674550535
Employee cost0.00173150126183156142
EBITDA(4.66)(25.92)(20.07)(97.96)(13.19)75.189.53
EBITDA margin-0.7%-4.6%-3.6%-21.3%-2.0%+12.0%+1.8%
Depreciation33.0634.8136.7139.1243.7845.5943.22
Interest6.053.883.584.44181185174
Profit before tax(7.37)(7.96)1.4712.801,449(146)(178)
Tax(0.21)0.772.9846.553711.9516.64
Net profit(24.44)(42.65)(33.97)(94.64)(197)(148)(160)
Net profit margin-3.8%-7.6%-6.1%-20.6%-29.8%-23.6%-29.4%
EPS (₹)(0.88)(1.37)(0.19)(5.43)176.05(24.11)(31.72)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.7913.3312.1211.116.136.136.13
Reserves & surplus807807814816849(256)139
Shareholders' funds (net worth)844842848849877(229)199
Minority interest(5.96)(4.17)(3.82)(3.49)(2.98)(3.00)(3.04)
Secured loans0.000.000.000.240.29760709
Unsecured loans15.0015.0015.0015.0033.8760.0333.55
Total debt15.0015.0015.0015.2434.16820742
Total liabilities8908999099219838131,064
Assets
Gross block1,3871,3461,3271,3311,3171,2621,275
Net block576567582600622609657
Capital work in progress14412810242.3217.2634.4224.01
Investments10.103.2240.4313.495.070.075.58
Inventories193214178202213174148
Sundry debtors73.5272.5657.4260.0981.6684.6868.52
Cash & bank balances64.3710713922658313689.75
Loans & advances17218069.9860.7367.90116377
Total current assets503573445549946511683
Total current liabilities349367309330776365326
Net working capital154206136219169146357
Total assets8908999099219838131,064
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash82.1347.1739.8550.3552.0840.2214.47
Net cash from operating activities16.69(27.37)(0.10)(422)(108)107(30.47)
Net cash from investing activities(40.46)64.9810.234301,283(47.79)(34.52)
Net cash from financing activities(1.06)(2.66)(2.81)(18.37)(1,176)(47.11)90.74
Net change in cash(24.82)34.957.32(10.50)(1.74)11.8625.75
Closing cash64.3710713922658313689.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.4%-0.0%+21.6%-30.4%+5.8%+14.8%-
EBITDA growth+82.0%-29.2%+79.5%-642.7%-117.5%+688.9%-
PBT growth+7.4%--88.5%-99.1%+9998.0%+18.0%-
Net income growth+42.7%-25.6%+64.1%+52.0%-33.4%+7.6%-
Revenue CAGR (3Y)+11.6%-5.4%-3.6%-5.4%+13.1%+1.8%0.0%
EBITDA CAGR (3Y)-63.8%+25.3%---53.9%-3.5%-41.3%
Profitability & leverage
Net income margin-1.1%-1.6%-0.3%-7.3%+163.1%-23.6%-35.7%
Return on capital employed--4.3%-3.3%-9.5%-5.1%0.0%0.0%
Return on net worth--5.1%-4.1%-11.1%-60.8%0.0%0.0%
Debt / equity-0.020.020.031.320.002.53
Long-term debt / equity-0.020.020.031.230.002.19
Interest cover-16.04-6.39-6.31-3.24-317.43626.36-516.41
Efficiency & per share
Fixed asset turnover-0.420.420.350.510.490.41
Inventory turnover-2.862.942.223.423.884.75
Debtors turnover-8.609.526.497.958.166.92
EPS (₹)(0.88)(1.37)(0.19)(5.43)176.05(24.11)(31.72)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00132.76133.94134.20139.59(40.87)23.67
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13511199.3190.8111267.9010876.64
Revenue growth (YoY)+20.0%+63.7%-8.4%+18.5%+97.4%---
Other income6.065.603.843.614.956.093.323.41
Total expenses12711110110511586.4793.0469.90
EBITDA7.300.30(1.38)(13.70)(3.02)(18.57)15.396.74
EBITDA margin+5.4%+0.3%-1.4%-15.1%-2.7%-27.3%+14.2%+8.8%
Depreciation4.474.184.894.914.774.915.215.09
Interest6.896.337.045.936.004.643.853.76
Profit before tax2.00(4.61)(9.47)(20.93)(8.84)(22.03)9.651.30
Tax0.61(4.43)(2.11)(5.29)(2.14)(9.64)0.000.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue413310360257236344158
Revenue growth+33.4%-13.8%+39.9%+9.2%-31.5%+117.3%-
Other income18.0016.6224.9134.4412.5720.7530.88
Total expenses431317345320308343293
Employee cost10097.0286.5371.0372.5059.4746.64
EBITDA(17.84)(6.92)14.15(62.62)(72.69)0.46(135)
EBITDA margin-4.3%-2.2%+3.9%-24.4%-30.9%+0.1%-85.2%
Depreciation18.7520.2921.0924.5026.4326.5726.91
Interest25.3115.4613.7810.067.047.525.27
Profit before tax(43.90)(26.05)4.19(62.74)(93.59)(12.88)(136)
Tax(13.97)(10.83)0.6624.790.001.5617.10
Net profit(29.93)(15.28)3.48(92.83)(93.60)(17.70)(122)
Net profit margin-7.2%-4.9%+1.0%-36.1%-39.8%-5.2%-77.0%
EPS (₹)(4.88)(2.49)0.58(14.29)(15.28)(2.36)(24.99)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.7913.3312.1211.116.136.136.13
Reserves & surplus257286301298387480833
Shareholders' funds (net worth)294321335331415508893
Secured loans0.000.000.000.240.295.0512.44
Unsecured loans25622111997.2383.8760.0354.80
Total debt25622111997.4784.1665.0867.24
Total liabilities584572480448515594978
Assets
Gross block883863901909908893905
Net block417416423435454464499
Capital work in progress13111996.5427.850.8812.973.74
Investments0.270.270.270.270.270.272.55
Inventories12615210811612987.0499.23
Sundry debtors30.6820.8511.0812.2723.3235.2917.69
Cash & bank balances8.1262.1711.9643.2542.6988.9660.61
Loans & advances11989.9252.5327.5253.5781.26437
Total current assets284325184199249293614
Total current liabilities266283249251247197161
Net working capital18.4641.57(65.64)(51.66)2.1396.03454
Total assets584572480448515594978
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash38.505.096.015.338.6614.924.96
Net cash from operating activities(40.17)3.9433.07(10.74)(52.69)38.27(82.86)
Net cash from investing activities(18.46)(60.60)(46.80)2.4139.54(37.32)(16.58)
Net cash from financing activities22.5490.0712.829.019.83(7.20)109
Net change in cash(36.09)33.41(0.91)0.67(3.32)(6.26)9.96
Closing cash8.1262.1711.9643.2542.6988.9660.61
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+33.4%-13.8%+39.9%+9.2%-31.5%+117.3%-
EBITDA growth-157.8%-148.9%+122.6%+13.9%-+100.3%-
PBT growth-68.5%-+9998.0%+33.0%-626.6%+90.5%-
Net income growth-95.9%-539.1%+103.8%+0.8%-428.8%+85.5%-
Revenue CAGR (3Y)+17.2%+9.6%+1.5%+17.6%+34.8%+23.2%-33.2%
EBITDA CAGR (3Y)-34.2%-54.3%+213.3%-22.5%-20.9%--
Profitability & leverage
Net income margin-7.2%-4.9%+1.0%-34.1%-39.7%-4.2%-96.8%
Return on capital employed0.0%0.0%+3.3%0.0%0.0%-1.1%-8.2%
Return on net worth0.0%0.0%+0.9%0.0%0.0%-2.5%-18.6%
Debt / equity0.780.520.320.240.160.090.58
Long-term debt / equity0.640.410.320.240.160.090.42
Interest cover-69.17-56.82-198.56-11.55-7.10-28.80-3.26
Efficiency & per share
Fixed asset turnover0.470.350.400.280.260.380.18
Inventory turnover2.972.383.212.102.183.692.23
Debtors turnover16.0519.4130.8014.458.0412.977.37
EPS (₹)(4.88)(2.49)0.58(14.29)(15.28)(2.36)(24.99)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)43.0347.7250.2049.6364.2479.43136.97
Want more history and ratios?
You're viewing the latest exchange-filed financials for Panacea Biotec Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Auditor Details of Panacea Biotec Limited

Panacea Biotec Limited is audited by Walker Chandiok & Co LLP for the financial year 2024.

NameStatusAppointment DateCessation Date
Walker Chandiok & Co LLPLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Panacea Biotec Limited

Panacea Biotec has 9 current directors and 23 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ankesh Jain
Also directs: Panacea Biotec Pharma Limited, Adveta Power Private Limited
Whole-Time Director01 Apr 201610 Years 6 MonthsCurrent
Sandeep Jain
Also directs: Everwise Ventures LLP, Panera Biotec Private Limited, Neophar Alipro Limited
Managing Director15 Nov 198441 Years 10 MonthsCurrent
Rajesh Jain
Also directs: Panera Biotec Private Limited, Panacea Biotec Pharma Limited, Adveta Power Private Limited
Managing Director25 Nov 200619 Years 10 MonthsCurrent
Krishan Kumar Jalan
Also directs: Pipan Oils Limited, Titagarh Rail Systems Limited, PNC Infratech Limited and 4 more
Director14 Feb 20251 Years 7 MonthsCurrent
Harshet Jain
Also directs: MD Next Life Sciences LLP
Whole-Time Director14 Feb 20251 Years 7 MonthsCurrent
Venkatesh Sarvasiddhi
Also directs: Indiaspark (OPC) Private Limited
Director14 Feb 20251 Years 7 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Shareholding Pattern of Panacea Biotec Limited

Shareholding for the quarter ended Sep 2026: promoters hold 72.50%, foreign institutional investors hold 2.30%, domestic institutional investors hold 2.30% and retail and other public shareholders hold 23.00%.

Promoters: 72.50%DII (Domestic Institutional): 2.30%FII (Foreign Institutional): 2.30%Retail & Others: 23.00%
Sep 2026
QUARTER
72.50% Promoters
2.30% DII (Domestic Institutional)
2.30% FII (Foreign Institutional)
23.00% Retail & Others
Promoter holding - history
Now 72.50% · Sep 2026High 72.50% · Dec 2025Low 72.50% · Dec 2025
71%71.8%72.5%73.3%74%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 72.50%Mar 2026: 72.50%Jun 2026: 72.50%Sep 2026: 72.50%72.50%72.50%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters72.50%72.50%72.50%72.50%
Public27.50%27.50%27.50%27.50%

Charges & Borrowings of Panacea Biotec Limited

Open charges
₹739.69 Cr
Satisfied charges
₹3,545.32 Cr
Breakdown by lending institutions
Others₹739.69 Cr
Latest charge details
DateLenderAmountStatus
06 Apr 2019Others₹739.69 CrOpen
05 Jan 2022Axis Bank Limited₹29.61 LakhSatisfied
04 Feb 2020Others₹754.44 CrSatisfied
14 Nov 2017Others₹5.29 CrSatisfied
27 Dec 2014Sbicap Trustee Company Limited₹934.27 CrSatisfied

Total charge records: 39 View all charges

MSME Payment Delays by Panacea Biotec Limited

Panacea Biotec Limited has 46 MSME Form 1 returns on record between 2009 and 2024, listing 2,403 overdue payments to 221 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 221)

SupplierAmount dueDue sinceReported on
an individual supplier••••••••••••
United Bio Fuel Industries••••••••••••
Oasis Tours India Private Limited••••••••••••
Scigenics (India) Private Limited••••••••••••
Url Aseptic Automation Inc.••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 46 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance at Panacea Biotec Limited

Panacea Biotec Limited has a workforce of 1,173 employees as of Mar 08, 2025.

Employee count
1,173
Active EPFO establishments
1
Employee growth
4.08%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Group Structure of Panacea Biotec Limited

Panacea Biotec has 2 subsidiary companies, 1 joint venture, and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

2
Subsidiary companies
1
Joint ventures
1
Associated companies
Key Subsidiaries
Company NameCINShares Held
Panacea Biotec Pharma LimitedU24299DL2019PLC347566-
Meyten Realtech Private LimitedU70109PB2019PTC049328-

Showing major subsidiaries. Total: 2.

Name History of Panacea Biotec Limited

Panacea Biotec has undergone 2 name changes throughout its history. The company was previously known as Panacea Drugs Ltd, and Panacea Drugs Pvt Ltd. The current legal name is Panacea Biotec Limited.

Company NameStatus
Panacea Biotec LimitedCurrent
Panacea Drugs LtdPrevious
Panacea Drugs Pvt LtdPrevious

CIN History of Panacea Biotec Limited

Panacea Biotec has one previous CIN (Corporate Identification Number): U33117PB1984PLC022350. The current CIN is L33117PB1984PLC022350, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L33117PB1984PLC022350Current
U33117PB1984PLC022350Previous

News related to Panacea Biotec Limited

Recent Activity on Panacea Biotec Limited

Panacea Biotec Limited has 53 board changes on record since 1984: 33 appointments and 20 cessations. The latest: Narotam Kumar Juneja ceased to be Director on 31 Mar 2025.

AGM
Panacea Biotec Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Panacea Biotec Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chandigarh.
Ceased
Narotam Kumar Juneja ceased to be Director.
Ceased
Manjula Upadhyay ceased to be Director.
Appointed
Harshet Jain was appointed as Whole-Time Director.
Appointed
Krishan Kumar Jalan was appointed as Director.
Appointed
Rajender Pal Singh was appointed as Director.
Appointed
Sanjay Trehan was appointed as Whole-Time Director.
Appointed
Venkatesh Sarvasiddhi was appointed as Director.
Appointed
Rajesh Jain was appointed as Director.
Ceased
Bhupinder Singh ceased to be Director.
Ceased
Krishna Murari Lal ceased to be Director.

143 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Panacea Biotec Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Panacea Biotec Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Panacea Biotec Limited

Panacea Biotec has 25 GST registrations: 23 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
25
Active
23
Cancelled / inactive
2
GSTINStateStatusRegistered on
03AAACP5335J1ZMPunjabActive01 Jul 2017
02AAACP5335J2ZNHimachal PradeshActive01 Jul 2017
04AAACP5335J1ZKChandigarhActive01 Jul 2017
05AAACP5335J1ZIUttarakhandActive01 Jul 2017
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Panacea Biotec Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Panacea Biotec Limited

Panacea Biotec is an active public limited company based in Lalru, Punjab, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 02 February 1984 (42+ years old) and is registered under CIN L33117PB1984PLC022350. Listed on BSE: 531349 and NSE: PANACEABIO.

Panacea Biotec reported revenue of ₹639.77 Cr for FY 2025-26 (up 14.4% YoY) based on consolidated financials.

Panacea Biotec has 9 current directors:

The GSTIN of Panacea Biotec is 03AAACP5335J1ZM, registered in Punjab. The company has 25 GST registrations in all, of which 23 are active and 2 are cancelled or inactive. Other active GSTINs include 02AAACP5335J2ZN (Himachal Pradesh), 04AAACP5335J1ZK (Chandigarh), 05AAACP5335J1ZI (Uttarakhand).

The CIN (Corporate Identification Number) of Panacea Biotec is L33117PB1984PLC022350. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Panacea Biotec is listed on both BSE (code: 531349) and NSE (symbol: PANACEABIO).

Panacea Biotec has 18 court cases on record: 14 filed by the company and 4 filed against it. 2 are pending. Most are in the district courts.

Panacea Biotec was incorporated on 02 February 1984, making it 42+ years old. It is registered with the Registrar of Companies, Chandigarh.

Narotam Kumar Juneja ceased to be Director on 31 Mar 2025. Manjula Upadhyay ceased to be Director on 29 Mar 2025. Harshet Jain was appointed as Whole-Time Director on 14 Feb 2025. Panacea Biotec has 53 board changes on record in total.

Panacea Biotec has 46 MSME Form 1 returns on record between 2009 and 2024, listing 2,403 overdue payments to 221 micro and small suppliers. The latest return was filed on 30 Apr 2024.

Panacea Biotec can be reached through the website panaceabiotec.com. Its registered office is in Lalru, Punjab, India.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available